Renal transplant recipients and chronic liver disease: Statistical evaluation of predisposing factors

A. Aroldi, A. Tarantino, G. Montagnino, M. Paparella, B. Cesana, M. G. Rumi, C. Ponticelli

Research output: Contribution to journalArticle

Abstract

278 azathioprine and methylprednisolone (AZA)-treated and 406 ciclosporin (CS) treated patients with a kidney graft functioning for more than 1 year were investigated for the presence of chronic liver disease (CLD), defined as an increase in transaminases of 1.5 times the upper normal limits for a period of at least 12 months. The prevalence of CLD was 36 and 27% in the two groups, respectively. The univariate analysis showed that male sex, alcohol abuse and HBsAg positivity correlated with CLD onset in the AZA group while blood transfusions, length of dialysis treatment, pretransplantation CLD, HBsAg positivity and ferritin levels over 800 ng/ml correlated with CLD onset in CS. The multivariate analysis identified male sex and HBsAg positivity in the AZA group and age over 18 years, high ferritin levels and HBsAg positivity in the CS group as risk factors predictive of CLD onset. Liver failure represented the 4th cause of death in the AZA group but 1 of the 2 most important causes of death in CS in the long term. However, these drawbacks were overcome by the overall low mortality rate in CS. Therefore, renal transplantation should not be refused to patients positive for HBsAg and/or with preexisting liver disease.

Original languageEnglish
Pages (from-to)290-292
Number of pages3
JournalNephron
Volume61
Issue number3
Publication statusPublished - 1992

Fingerprint

Causality
Liver Diseases
Chronic Disease
Hepatitis B Surface Antigens
Kidney
Cyclosporine
Ferritins
Cause of Death
Preexisting Condition Coverage
Liver Failure
Methylprednisolone
Azathioprine
Transaminases
Transplant Recipients
Blood Transfusion
Kidney Transplantation
Alcoholism
Dialysis
Multivariate Analysis
Age Groups

Keywords

  • Chronic liver disease
  • Graft survival
  • HBV infection
  • Renal transplantation

ASJC Scopus subject areas

  • Nephrology

Cite this

Aroldi, A., Tarantino, A., Montagnino, G., Paparella, M., Cesana, B., Rumi, M. G., & Ponticelli, C. (1992). Renal transplant recipients and chronic liver disease: Statistical evaluation of predisposing factors. Nephron, 61(3), 290-292.

Renal transplant recipients and chronic liver disease : Statistical evaluation of predisposing factors. / Aroldi, A.; Tarantino, A.; Montagnino, G.; Paparella, M.; Cesana, B.; Rumi, M. G.; Ponticelli, C.

In: Nephron, Vol. 61, No. 3, 1992, p. 290-292.

Research output: Contribution to journalArticle

Aroldi, A, Tarantino, A, Montagnino, G, Paparella, M, Cesana, B, Rumi, MG & Ponticelli, C 1992, 'Renal transplant recipients and chronic liver disease: Statistical evaluation of predisposing factors', Nephron, vol. 61, no. 3, pp. 290-292.
Aroldi A, Tarantino A, Montagnino G, Paparella M, Cesana B, Rumi MG et al. Renal transplant recipients and chronic liver disease: Statistical evaluation of predisposing factors. Nephron. 1992;61(3):290-292.
Aroldi, A. ; Tarantino, A. ; Montagnino, G. ; Paparella, M. ; Cesana, B. ; Rumi, M. G. ; Ponticelli, C. / Renal transplant recipients and chronic liver disease : Statistical evaluation of predisposing factors. In: Nephron. 1992 ; Vol. 61, No. 3. pp. 290-292.
@article{e4bff6b6a87f4ff59965982e9e40c9ab,
title = "Renal transplant recipients and chronic liver disease: Statistical evaluation of predisposing factors",
abstract = "278 azathioprine and methylprednisolone (AZA)-treated and 406 ciclosporin (CS) treated patients with a kidney graft functioning for more than 1 year were investigated for the presence of chronic liver disease (CLD), defined as an increase in transaminases of 1.5 times the upper normal limits for a period of at least 12 months. The prevalence of CLD was 36 and 27{\%} in the two groups, respectively. The univariate analysis showed that male sex, alcohol abuse and HBsAg positivity correlated with CLD onset in the AZA group while blood transfusions, length of dialysis treatment, pretransplantation CLD, HBsAg positivity and ferritin levels over 800 ng/ml correlated with CLD onset in CS. The multivariate analysis identified male sex and HBsAg positivity in the AZA group and age over 18 years, high ferritin levels and HBsAg positivity in the CS group as risk factors predictive of CLD onset. Liver failure represented the 4th cause of death in the AZA group but 1 of the 2 most important causes of death in CS in the long term. However, these drawbacks were overcome by the overall low mortality rate in CS. Therefore, renal transplantation should not be refused to patients positive for HBsAg and/or with preexisting liver disease.",
keywords = "Chronic liver disease, Graft survival, HBV infection, Renal transplantation",
author = "A. Aroldi and A. Tarantino and G. Montagnino and M. Paparella and B. Cesana and Rumi, {M. G.} and C. Ponticelli",
year = "1992",
language = "English",
volume = "61",
pages = "290--292",
journal = "Experimental Nephrology",
issn = "0028-2766",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Renal transplant recipients and chronic liver disease

T2 - Statistical evaluation of predisposing factors

AU - Aroldi, A.

AU - Tarantino, A.

AU - Montagnino, G.

AU - Paparella, M.

AU - Cesana, B.

AU - Rumi, M. G.

AU - Ponticelli, C.

PY - 1992

Y1 - 1992

N2 - 278 azathioprine and methylprednisolone (AZA)-treated and 406 ciclosporin (CS) treated patients with a kidney graft functioning for more than 1 year were investigated for the presence of chronic liver disease (CLD), defined as an increase in transaminases of 1.5 times the upper normal limits for a period of at least 12 months. The prevalence of CLD was 36 and 27% in the two groups, respectively. The univariate analysis showed that male sex, alcohol abuse and HBsAg positivity correlated with CLD onset in the AZA group while blood transfusions, length of dialysis treatment, pretransplantation CLD, HBsAg positivity and ferritin levels over 800 ng/ml correlated with CLD onset in CS. The multivariate analysis identified male sex and HBsAg positivity in the AZA group and age over 18 years, high ferritin levels and HBsAg positivity in the CS group as risk factors predictive of CLD onset. Liver failure represented the 4th cause of death in the AZA group but 1 of the 2 most important causes of death in CS in the long term. However, these drawbacks were overcome by the overall low mortality rate in CS. Therefore, renal transplantation should not be refused to patients positive for HBsAg and/or with preexisting liver disease.

AB - 278 azathioprine and methylprednisolone (AZA)-treated and 406 ciclosporin (CS) treated patients with a kidney graft functioning for more than 1 year were investigated for the presence of chronic liver disease (CLD), defined as an increase in transaminases of 1.5 times the upper normal limits for a period of at least 12 months. The prevalence of CLD was 36 and 27% in the two groups, respectively. The univariate analysis showed that male sex, alcohol abuse and HBsAg positivity correlated with CLD onset in the AZA group while blood transfusions, length of dialysis treatment, pretransplantation CLD, HBsAg positivity and ferritin levels over 800 ng/ml correlated with CLD onset in CS. The multivariate analysis identified male sex and HBsAg positivity in the AZA group and age over 18 years, high ferritin levels and HBsAg positivity in the CS group as risk factors predictive of CLD onset. Liver failure represented the 4th cause of death in the AZA group but 1 of the 2 most important causes of death in CS in the long term. However, these drawbacks were overcome by the overall low mortality rate in CS. Therefore, renal transplantation should not be refused to patients positive for HBsAg and/or with preexisting liver disease.

KW - Chronic liver disease

KW - Graft survival

KW - HBV infection

KW - Renal transplantation

UR - http://www.scopus.com/inward/record.url?scp=0026763088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026763088&partnerID=8YFLogxK

M3 - Article

C2 - 1501727

AN - SCOPUS:0026763088

VL - 61

SP - 290

EP - 292

JO - Experimental Nephrology

JF - Experimental Nephrology

SN - 0028-2766

IS - 3

ER -